Novartis Chief Executive Vas Narasimhan called the moment "historic", saying in a statement that Sandoz started out from a position of strength as a global leader in the area of generics and biosimilars. The firm initiated the long-awaited spin-off following mounting pricing pressures in the U.S. off-patent drug sector.